EFFECTIVE STEPS TOWARDS THE APPLICATION OF SILVER NANOPARTICLES AS SAFE SYSTEMIC INFECTION CONTROLLING AGENTS

Prasanta Kumar Maiti, Rehana Parveen, Paramita Ghosh

Abstract


Silver nanoparticles (AgNPs) possess potent pan-microbicidal properties with non-specific synergisms for different
antimicrobial agents, yet none found suitable for systemic use for potential risk of host cell damage. AgNPs prepared
from silver nitrate using dextrose as reducing and human serum as mixture of stabilizing agents, also show all
antimicrobial properties. There is least possibility of internalization by receptor-ligand attachment in human cells and
liberation of any toxic components after de-capping for bio-mimicking outer coat. For their antimicrobial actions against
different multi-drug resistant pathogens at any point of cell cycle and wide range nonspecific synergism with different
antibiotics, can be used at safe low dosage with or without synergistic antibiotics. In-vitro study on human liver cell-line
(WRL-68) and in-vivo study in mice model indicated wide margin of safety. Thus, major life-threatening infections caused
by super-bugs can be managed in future by such safe systemic useable Nano-antimicrobials.


Keywords


Silver nanoparticles, Anti-microbial agent, Systemic usable drug, Cytotoxicity.

Full Text:

PDF

References


Neu H. The crisis in antibiotic resistance. Science, 1992; 257:1064-73.

Franci G, Falanga A , Galdiero S , Palomba L, Rai M , Morelli G and Galdiero M.S Nanoparticles as Potential Antibacterial Agents. Molecules, 2015;20:8856-74. doi:10.3390/molecules20058856.

Matsumura Y, Yoshikata K, Kunisaki S, Tsuchido T. Mode of bactericidal action of silver zeolite and its comparison with that of silver nitrate. Appl Environ Microbiol,2003; 69:4278.

Burdusel AC, Gherasim O, Grumezescu AM, Mogoanta L, Ficai A and Andronescu E. Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview. Nanomaterials. 2018; 8: 681. doi:10.3390/nano8090681.

Shrivastava S, Bera T, Roy A, Singh G, Ramachandrarao P, Dash D. Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology,2007; 18:225103. doi:10.1088/0957-4484/18/22/225103.

You C, Han C, Wang X, Zheng Y, Li Q, Hu X. The progress of silver nanoparticles in the antibacterial mechanism, clinical application and cytotoxicity. Mol Biol Rep,2012; 39: 9193–201. doi: 10.1007/ s11033-012-1792-8 PMID: 22722996.

Yan X, He B, Liu L, Qu G, Shi J, Hu L, Jiang G. Antibacterial mechanism of silver nanoparticles in pseudomonas aeruginosa: Proteomics approach. Metallomics,2018; 10: 557–64.

Alshareef A., Laird K, Cross RBM. Shape-dependent antibacterial activity of silver nanoparticles on Escherichia coli and Enterococcus faecium bacterium. Appl. Surf. Sci.2017; 424: 310–15.

Garza-Ocañas L, Ferrer DA, Burt J, Diaz-Torres LA, Ramirez Cabrera M, Tamez Rodriguez V, et al. Biodistribution and long-term fate of silver nanoparticles functionalized with bovine serum albumin in rats. Metallomics,2010; 2: 204–10.

Huh A.J., Kwon Y.J. “Nano antibiotics” A new paradigm for treating infectious diseases using nanomaterials in the antibiotic’s resistant era. Journal of Controlled Release,2011; 156:131-33.

Song K, Lee S, Park T, Lee B. Preparation of colloidal silver nanoparticles by chemical reduction method. Korean J Chem. Eng.2009; 26:153–55.

Gupta, A.; Matsui, K.; Lo, J.F.; Silver, S. Molecular basis for resistance to silver cations in salmonella. Nat. Med,1999; 5:183–88.

Hwang I.S., Hwang J.H., Choi H., Kim K.J., Lee D.G. Synergistic effects between silver nanoparticles and antibiotics and the mechanisms involved. J MedMicrobiol,2012; 61:1719-26.

Panacek A, Smekalova M, Kilianova M, Prucek R, Bogdanova K, Vecerova R, et al. Strong and Nonspecific Synergistic Antibacterial Efficiency of Antibiotics Combined with Silver Nanoparticles at Very Low Concentrations Showing No Cytotoxic Effect. Molecules, 2016; 21: 26. doi:10.3390/molecules21010026.

Ansari MA, Khan AA, Cameotra SS, Alzohairy MA. Anti-biofilm efficacy of silver nanoparticles against MRSA and MRSE isolated from wounds in a tertiary care hospital. Indian J Med Microbiol, 2015; 33:101-109.

Kreytsberg GN,Gracheva IE, Kibrik BS, Golikov IV. Antituberculous effect of silver nanoparticles. Journal of Physics: Conference Series,2011; 291: 012030. doi:10.1088/1742-6596/291/1/012030.

Maiti PK, Haldar J, Mukherjee P, DeyR. Anaerobic culture on growth efficient bi-layered culture plate in a modified candle jar using a rapid and slow combustion system. Indian J Med Microbiol, 2013; 31:173-76.

Maiti PK, Ghosh A, Parveen R, Saha A, Choudhury MG. Preparation of carboxy-methyl cellulose capped nanosilver particles and their antimicrobial evaluation by automated device. Applied Nanoscience, 2019; 9:105-11 doi.org/10.1007/s13204-018-0914-6.

Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. Am. J. Inf. Cont, 1999; 27:344-50.

Netchareonsirisuk P, Puthong S, Dubas S, Palaga T, Komolpis K. Effect of capping agents on the cytotoxicity of silver nanoparticles in human normal and cancer skin cell lines. J Nanopart Res, 2016;18:322-32.

Ordzhonikidze CG. , Ramaiyya LK. , Egorova EM. , Rubanovich AV. Genotoxic Effects of Silver Nanoparticleson Mice in Vivo. Actanaturae, 2009; 1: 99-101.

Huang H, Lai W, Cui M, Liang L, Lin Y, Fang Q, Liu Y, Xi AN L. Evaluation of Blood Compatibility of Silver Nanoparticles. Scientific Reports, 2016; 6: 25518.DOI: 10.1038/srep25518.

Gnanadhas DP, ThomasMB,Thomas R, Raichur AM, Chakravortty D. Interaction of Silver Nanoparticles with Serum Proteins Affects Their Antimicrobial Activity In Vivo . Antimicrobial Agents and Chemotherapy, 2013; 57:4945-55.

Monteiro-Riviere NA, Samberg ME, Oldenburg SJ, RiviereJE. Protein binding modulates the cellular uptake of silver nanoparticles into human cells: implications for in vitro to in vivo extrapolations? Toxicol. Lett, 2013; 220:286–93.

Tauran Y, Brioude A, Coleman AW, Rhimi M, Kim B. Molecular recognition by gold, silver and copper nanoparticles. World J Biol Chem, 2013; 4: 35-63.

DarabiSahneh F, Scoglio C, Riviere J. Dynamics of Nanoparticle-Protein Corona Complex Formation: Analytical Results from Population Balance Equations. PLoS ONE,2013; 8: e64690. doi:10.1371/journal.pone.0064690.

Saha K, Moyano DF, Rotello VM. Protein coronas suppress the hemolytic activity of hydrophilic and hydrophobic nanoparticles, Mater Horiz, 2014; 1: 102-105. DOI: 10.1039/c3mh00075c.

Mirshafiee V, Mahmoudi M, Lou K, Cheng J and Kraft ML. Protein corona significantly reduces active targeting yield. Chem. Commun, 2013; 49:2557-59. DOI: 10.1039/c3cc37307j.

Nguyen VH, Lee BJ. Protein corona: a new approach for nanomedicine design. International Journal of Nanomedicine,2017; 12: 3137–151.

Loeschner K, Hadrup N, Qvortrup K, Larsen A, Gao X, Vogel U, et-al. Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate. Part Fibre Toxicol, 2011; 8:18. doi:10.1186/1743-8977-8-18.

Munger, MA, RadwanskiP,Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, andDeering-Rice CE. In Vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomed Nanotechnol, 2014; 10: 1-9. doi:10.1016/j.nano.2013.06.010.

Schleh C, Semmler-Behnke M, Lipka J, Wenk A, Him S, Schaffler M, et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology, 2012; 6:36-46.

Hamouda T, Myc A, Donovan B, Shih A, Reuter J, Baker J. A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. Microbiol Res, 2001; 156:1–7.

Li WR, Xie XB, Shi QS, Zeng HY, Ou-Yang YS, Chen YB. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol, 2010; 85:1115–22. doi: 10.1007/s00253-009-2159-5 PMID: 19669753.

Hsin YH, Chen CF, Huang S, Shih TS, Lai PS, and Chueh PJ. “The apoptotic effect of nanosilver is mediated by a ROS- and JNKdependent mechanism involving the mitochondrial pathway in NIH3T3 cells”.Toxicology Letters, 2008; 179: 130–39.

Cha K, Hong HW, Choi YG, Lee MJ, Park JH,Chae HK, Ryu G et al. Comparison of acute responses of mice livers to short-term exposure to nano-sized or micro-sized silver particles. Biotechnol. Lett, 2008; 30:1893–99.

Wong KKY, Liu X. Silver nanoparticles-the real ‘’silver bullet’’in clinical medicine. Med Chem Commun, 2010; 1: 125-131 [doi: 10.1039/c0md00069h.]

Neena D, Devraj KM, Bhagat AP. Role of Capping Agent in the Synthesis of Silver Nanoparticles. Journal of Pharmacy Research, 2012; 5(9):4710-12. Available online through www.jpronline.info


Refbacks

  • There are currently no refbacks.